Wealth Awesome
TSX open
Loading markets…
Interactive Brokers: options trading made simple with the IBKR Options Wizard.
Stocks/NASDAQ/CUE

Cue Biopharma (CUE : NASDAQ)

$4.76USD+1.93 (68.20%)Close of 2026-11-18

Common Stock

Follow CUE

CUE

Cue Biopharma

Source:WealthAwesomeWealthAwesome
↓ $17.57 (-78.68%)
30 day period
$2.83$15.24$27.66Oct 8Oct 29Nov 18

Performance

1 Day

+68.20%

1 Week

-74.49%

1 Month

-70.40%

YTD

-82.19%

The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.

Key Statistics

Market Cap

$102.43M

52W High

$45.50

52W Low

$4.97

P/E Ratio

-

50 Day MA

$23.94

200 Day MA

$21.57

Beta

2.81

Dividend Yield

-

Performance history

CUE returns since 2026

Cue Biopharma has traded since Jun 2026 in our data. Its deepest fall was −92.5% (Sep 2026 to Nov 2026).

1 year / yr

—

3 years / yr

—

5 years / yr

—

10 years / yr

—

Calendar-year returns

  • 2026*−82.2%

* Partial year (first year of data, or year to date).

$10,000 invested in CUE

  • 2026 (start of our data)$1,781
All-time high in our data
$38 on Sep 17, 2026 · now −87.4%

Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.

Awesome Portfolio™

Looking past CUE? Our 10 best Canadian stocks, in one list.

14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.

See the portfolio →

Technical Indicators

Price vs 50-Day SMA

↓Below 50 SMA

Price vs 200-Day SMA

↓Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
11/18/2026$3.41$4.77$3.27$4.76$4.7613,229,241
11/17/2026$13.02$13.52$2.83$2.83$2.834,229,479
11/16/2026$15.81$15.81$13.56$14.10$14.10211,343
11/13/2026$17.69$17.69$14.30$16.12$16.12274,955
11/12/2026$18.23$18.92$17.21$17.50$17.50147,421
11/11/2026$19.24$19.99$18.51$18.66$18.66122,973
11/10/2026$19.73$20.35$18.76$18.76$18.76132,863
11/9/2026$18.90$21.20$17.95$20.14$20.14187,454
11/6/2026$18.36$19.00$17.85$18.73$18.73205,562
11/5/2026$19.35$19.74$16.87$18.01$18.01141,747

Analyst Price Targets

Based on 3 analysts covering CUE · as of Oct 5, 2026

📈

Wall Street analysts forecast CUE stock price to rise 1748.7% over the next 12 months.

Consensus

Strong Buy

5.00 / 5.00

Avg. Target

US$88.00

+1748.7% Upside

Current Price

US$4.76

Last close

Analyst Breakdown (3 analysts)

Strong Buy 3
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on CUE's historical volatility

HistoricalForecast68%95%
US$0.01US$365.44US$730.87US$1096.31US$1461.74US$1827.17TodayJul 15Sep 17Nov 18Dec 31Feb 13Mar 28

30-Day Vol

510.3%

Annualized

90-Day Vol

311.2%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

US$3.98

Expected price

HorizonExpected68% Range (1σ)
30 trading daysUS$4.48US$0.77 – US$26.09
60 trading daysUS$4.23US$0.35 – US$50.97
90 trading daysUS$3.98US$0.19 – US$84.04

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Financials

Revenue (TTM)
$37.66M
EBITDA
$-97.28M
Profit Margin
0.00%
ROE (TTM)
-1603.48%
EPS (Diluted)
-29.59
Book Value
0.44

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

Free newsletter

The Tuesday Stock Pick

Tuesday morning

One Canadian stock and the case for it

  • The name with the biggest gap to analyst targets
  • The chart, insider buying and what is driving it
  • A plain-English bottom line, no hype

Free. One email a week. Unsubscribe any time.

Common Questions About CUE.US

Market movers

Recent NASDAQ movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
SKYASkyAI, Inc.$4.13+90.32%
CLROClearOne Inc$6.90+46.19%
AZIAutozi Internet Technology (Global) Ltd. Class A Ordinary Shares$1.04+42.45%
NURNuran Wireless Inc. Common Shares$0.50+33.76%
ANPARich Sparkle Holdings Limited Ordinary Shares$1.40+33.33%
ICUSeaStar Medical Holding Corporation$1.04+33.16%
HIHOHighway Holdings Limited$1.61+30.89%
HPAIHelport AI Limited Ordinary Shares$0.26+27.23%

Free with a Wealth Awesome account

Keep analysing CUE, free

  • Every WA Score, ranking and table
  • Insider track records and SEDI filings
  • Earnings history and analyst targets for every stock

Email only, no password, no card. Already a member? Use the same button to sign in.